Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill finish contract manufacturing organisation (CMO), has manufactured their first 10,000 vial batch at the company’s new facility in Stirling, UK. The project, delivered for one of Symbiosis’ long-standing clients, supports the development of a cancer immunotherapy currently in Phase III trials This production batch of 10,000 vials […]
Post Type Archives: News
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
– Secures the company’s first U.S.-based manufacturing site, strengthening and diversifying its global supply network – Additional investments planned to expand the site’s capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs – Underscores Samsung Biologics’ long-term dedication to the U.S. biopharmaceutical industry and supply chain Samsung Biologics, a […]
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus’ Board of Directors unanimously recommended that […]
Ophidion and Neuronasal Announce Parkinson’s Disease, Obesity, and Diabetes Partnership
Ophidion, an early-stage biopharmaceutical company developing non-invasive therapeutics for neurodegenerative disorders, and Neuronasal, a clinical-stage biotechnology company focused on nose-to-brain delivery of therapeutics for CNS disorders, announced a strategic partnership on December 15th, 2025. According to a company press release, the partnership will see the companies co-develop therapeutic candidates for Parkinson’s disease, obesity, and diabetes. […]
Sobi to Acquire Arthrosi Therapeutics in $1.5 Billion Deal
Sobi, a biopharmaceutical company developing treatments for rare diseases, announced plans to acquire Arthrosi Therapeutics, a clinical-stage biotechnology company developing a potentially best-in-class treatment for progressive and tophaceous gout, in a deal worth up to $1.5 billion on December 13th, 2025. According to a company press release, Sobi will pay approximately 950 million upfront to […]
Symeres earns first SBTi approval as part of long-term sustainability journey
Symeres, a leading contract research, development, and manufacturing organisation (CRDMO), has received its first approval from the Science Based Targets initiative (SBTi) for its greenhouse gas (GHG) emissions reduction targets. This marks a major milestone in Symeres’ environmental strategy and affirms its commitment to building a more sustainable, low-carbon future. This validation confirms the company’s […]
Sanofi Acquires Rights to Alzheimer’s Drug in $1.04 Billion Deal
ADEL, a biopharmaceutical company developing therapies for neurodegenerative diseases, announced an exclusive worldwide license agreement with Sanofi on December 15th, 2025. The agreement will see Sanofi acquire the rights to ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer’s disease, in a deal valued at up to $1.04 billion. According to a company press release, ADEL-Y01 […]
FDA Expands Label for Johnson & Johnson’s Akeega
Johnson & Johnson announced FDA approval of a label expansion for Akeega (niraparib and abiraterone acetate dual-action tablet; niraparib and abiraterone acetate) plus prednisone (niraparib and abiraterone acetate plus prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC) on December 12th, 2025. Patients are eligible for the therapy following results from an FDA-approved test for genetic […]
FDA Approves Pair of Gonorrhea Treatments
FDA approved two unrelated treatments for Uncomplicated Urogenital Gonorrhea (gonorrhea) back-to-back from December 11th to 12th, 2025. FDA granted GSK’s Bluejapa (gepotidacin) a label expansion for the indication on the 11th, while Innoviva’s Nuzolvence (zoliflodacin) received the nod on the 12th. Both treatments are indicated for patients aged 12 years and older who have few […]
PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies
PolyPeptide Group AG, a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic alliance to enhance supply chain resilience, improve operational efficiency, and support the long-term growth of both organizations. Through this alliance, PolyPeptide will broaden its sourcing options for key materials, establishing a more robust and flexible supply […]